Sickle cell disease is a genetic blood disorder characterised by the production of abnormal haemoglobin, which causes red blood cells to become rigid and sickle-shaped. These cells tend to clump ...

Novo Nordisk's rare disease unit awaits Phase 3 data for etavopivat in sickle cell disease, aiming for 50% VOC reduction ...

Discover effective strategies to minimize sickle cell pain crises and avoid hospitalizations. Leading hematologists share ...

Recent research highlights the significant underuse of disease-modifying therapies for sickle cell disease, despite their ...

A new type of bone marrow transplant can cure sickle cell disease with only half of the donor's cell proteins matching, ...

Sickle Cell Disease Treatment Market is estimated to be valued at USD 3.20 Bn in 2025 and is expected to reach USD 8.81 Bn by 2032 exhibiting a CAGR of 15.6% Mr. Shah Coherent Market Insights Pvt. Ltd ...

Sickle cell anemia, also called drepanocytosis, is a blood disorder or hemoglobin disorder that changes the shape of red blood cells. The abnormally shaped red blood cells interfere with the delivery ...

In September 2024, Pfizer voluntarily withdrew all lots of Oxbryta (voxelotor) for sickle cell disease (SCD) in all markets where it is approved. Pfizer's decision is based on the totality of ...

Three key players share the story of how fundamental discoveries in the laboratory became a first-of-its-kind therapy that promises to have a monumental impact on sickle cell disease patients around ...